Introduction {#Sec1}
============

Hearing deficits have been found in several lysosomal storage disorders including Gaucher disease (Bamiou et al. [@CR1]; Kaga et al. [@CR6]; Lacey and Terplan [@CR13])), Fabry disease (Hajioff et al. [@CR3]; Hegemann et al. [@CR4]; Keilmann et al. [@CR8]; Palla et al. [@CR15]; Schachern et al. [@CR17]), and Mucopolysaccharidoses (Komura et al. [@CR12]; Peck [@CR16]; Schachern et al. [@CR18]). Previously, we have detected hearing loss in four classic infantile Pompe patients as a new finding (Kamphoven et al. [@CR7]).

Pompe disease (also called glycogen storage disease type II or acid maltase deficiency) (OMIM 232300) is caused by deficiency of the lysosomal enzyme acid alpha-glucosidase (EC 3.2.1.20). This leads to progressive glycogen storage in several tissues, among which skeletal and cardiac muscle are the most important (van der Ploeg and Reuser [@CR25]; Engel et al. [@CR2]). The disease occurs in infants, children, and adults with a variable degree of disease severity and progression of muscle weakness. The clinical condition of patients with the so-called classic infantile form rapidly deteriorates, leading to death before the age of 1 year (van den Hout et al. [@CR23]; Kishnani et al. [@CR9]). Patients with other phenotypes show a more slowly progressive disease course (Winkel et al. [@CR27]). In the past, no treatment other than supportive care was available, but the recent introduction of enzyme replacement therapy has changed the prospect for patients (Kishnani et al. [@CR10], [@CR11]; Strothotte et al. [@CR19]; van Capelle et al. [@CR22]; Van den Hout et al. [@CR24]).

Although hearing loss is now increasingly recognized in classic infantile patients, the exact prevalence and type of hearing loss has never been investigated in a large group of patients, especially not in patients with more slowly progressive forms of the disease.

In this study, we analyzed repetitive auditory brainstem response measurements (ABRs) and pure tone audiometries before and after start of enzyme therapy in a cohort of 24 children: 11 patients with the classic infantile form and 13 patients with a less severe, juvenile form of the disease.

Patients and methods {#Sec2}
====================

Subjects {#Sec3}
--------

Twenty-four patients, 11 classic infantile and 13 juvenile patients, were enrolled in the present study. All patients were diagnosed with Pompe disease by detecting enzyme deficiency in leukocytes or fibroblasts, and by mutation analysis. Inclusion criteria for the infantile group were: symptoms of muscle weakness within 3 months after birth, hypertrophic cardiomyopathy at diagnosis, and severe GAA (the gene encoding acid α-glucosidase) mutations on both alleles. Inclusion criteria for the juvenile group were: all other children with Pompe disease having one GAA mutation on each allele, at least one of which not severe. Eleven of the juvenile patients and all classic infantile patients were enrolled in a prospective study investigating the safety and efficacy of enzyme replacement therapy with recombinant human acid α-glucosidase (20--40 mg/kg). The other two juvenile patients were diagnosed pre-symptomatically, and were enrolled in an observational study that monitored disease progression in untreated patients. Both studies were approved by the Institutional Review Board of the Erasmus Medical Center, and all patients and parents gave written informed consent. All hearing assessments were performed before start of enzyme therapy and at regular intervals thereafter, if applicable.

Hearing assessments {#Sec4}
-------------------

In the juvenile patients, routine pure-tone audiometry was performed. When abnormalities were detected, the test was repeated at regular intervals, and patients were seen by an ENT (ear, nose and throat) specialist.

In the classic infantile patient group, auditory brainstem evoked responses, oto-acoustic emissions, and impedance audiometry were performed before the start of treatment and at regular intervals thereafter. An experienced audiologist evaluated the test results.

Auditory tests {#Sec5}
--------------

Pure tone audiograms were made with a Madsen OB 822 audiometer (Copenhagen, Denmark) in a sound-proof room. Pure-tone threshold testing was performed for both air conduction and bone conduction. The average hearing threshold at frequencies 500, 1,000, 2,000, and 4,000 Hz was used to classify the type of hearing loss (conductive component in case of an air-bone gap \>15 dB) and to grade the amount of hearing loss according to the WHO definition of hearing impairment (WHO [@CR26]).

Auditory brainstem evoked responses were determined using the Euphra-1 system and a Jaeger-Toennies pre-amplifier. Click stimuli were presented at different levels with a repetition rate of 23/s via a TDH 49 headphone. The waveform was analyzed by an experienced audiologist, defining peak latencies of waves I (distal cochlear part of the VIIIth nerve), III (in between cochlear nucleus and the superior olivary complex), and V (between the superior olivary complex and the inferior colliculus). The amount of hearing loss was estimated from the detection threshold of peak V. The time interval between peaks I, III, and V at stimulus level of 90 dB was used to identify retrocochlear dysfunction.

To assess cochlear function, transient evoked otoacoustic emissions (OAE) were carried out using the ILO288 (Otodynamics, UK). Otoacoustic emissions are vibrations presumably produced by the outer hair cells in the cochlea. Presence of otoacoustic emissions indicates a normal reponse to auditory stimuli of the middle ear and cochlea. To assess middle ear function, impedance audiometry was performed with a standard clinical impedance meter (AT260; Interacoustics, USA). An abnormal result indicates middle ear dysfunction.

The origin of the hearing deficit (conductive, cochlear, retrocochlear) was estimated by the combined interpretation of the ABR, otoacoustic emissions, and impedance audiometry.

Statistical analysis {#Sec6}
--------------------

ABR waveform latencies and inter-peak time intervals were compared to reference values obtained in 150 children with normal hearing in the Erasmus MC Sophia Children's hospital, and were expressed as z-scores. A z-score represents the number of standard deviations from the mean. Waveform latencies and inter-peak time intervals were considered abnormal if the measured value was above a z-score of 1.96. The individual relationship between the different outcome measures and treatment time were analyzed using least-squares regression.

All data analyses were performed using SPSS for Windows version 15.

Results {#Sec7}
=======

Classic infantile Pompe patients {#Sec8}
--------------------------------

### Hearing loss {#Sec9}

Eleven classic infantile Pompe patients were included in the present study. Table [1](#Tab1){ref-type="table"} summarizes the clinical features of each of the patients. Table [2](#Tab2){ref-type="table"} tabulates the type of hearing loss found in each individual patient before start of treatment and after 1--6 years of treatment. Hearing loss was detected immediately after birth in some patients. There was no significant correlation between the age of the patients at their first hearing test and the severity of hearing loss. Baseline measurements were performed before start of enzyme therapy and revealed a sensorineural hearing loss in 9 of the 11 patients (for details, see Table [2](#Tab2){ref-type="table"}). In all these patients, latencies of peaks I and V as function of stimulus level suggested a cochlear origin of the hearing loss. Absent OAEs with normal middle ear function confirmed the cochlear dysfunction in 6 patients, while abnormal tympanograms prohibited a reliable interpretation of the OAE results in 2 patients. Two patients had normal cochlear function but showed evidence of retrocochlear pathology, as inter-peak latencies between waves I and V were significantly prolonged. Table 1Characteristics of 11 classic infantile Pompe patientsPatientAge first assessment (months)Gender (M/F)Motor status at first assessmentMotor status at final assessmentAge at final ABR (years)13MAxial hypotonia, head-lag, extremity movement +Walks unsupported627FParalysis legs, paresis armsTetraplegic638FParalysis legs, paresis armsTetraplegic242.5FAxial hypotonia, head-lag, extremity movement +/−Sits unsupported, † 4.2 years452MAxial hypotonia, head-lag, extremity movement +Walks unsupported, † 4.2 years461MAxial hypotonia, head-lag, extremity movement +Walks unsupported570.5FAxial hypotonia, head-lag, extremity movement +Walks unsupported580.1MAxial hypotonia, head-lag, extremity movement +Walks unsupported392MAxial hypotonia, head-lag, extremity movement +/−Sits unsupported3100.2FAxial hypotonia, head-lag, extremity movement +Walks unsupported1113.5FAxial hypotonia, head-lag, extremity movement +/−No gains, † 8 months--*ABR* Auditory brainstem response† DiedTable 2Summary of audiometric results of the 11 classic infantile patients at baseline and after a maximum period of 6 years of enzyme replacement therapy with recombinant human α-glucosidasePatientAgeRight earLeft earEHTTympOAEI--VIII--VEHTTympOAEI--VIII--VBaseline 13 m30NormalAbsentNormalN.A.60NormalAbsentNormalN.A. 27 m70NormalAbsentNormalN.A.90AbnormalAbsentNormalN.A. 38 m40NormalAbsentNormalN.A.40NormalAbsentNormalN.A. 42.5 m40AbnormalAbsentNormalN.A.60AbnormalAbsentNormalN.A. 52 m80NormalAbsentNormalN.A.60NormalAbsentNormalN.A. 61 m20NormalPresentProlonged2.220NormalPresentProlonged2.7 70.5 m50NormalAbsentNormalN.A.40NormalAbsentNormalN.A. 80.1 m10NormalPresentProlonged3.610NormalPresentProlonged2.5 92 m60??Prolonged3.360NormalAbsentNormalN.A. 102.5 m40NormalAbsentNormalN.A.40NormalAbsentNormalN.A. 113.5 m70AbnormalAbsentNormalN.A.70AbnormalAbsentNormalN.A.After maximum 6 years of enzyme replacement therapy 16 y80AbnormalAbsentNormalN.A.80AbnormalAbsentNormalN.A. 26 y70NormalAbsentNormalN.A.70NormalAbsentNormalN.A. 32 y60AbnormalAbsentProlonged2.380AbnormalAbsentProlonged3.3 44 y80AbnormalAbsentNormalN.A.90AbnormalAbsentNormalN.A. 54 y80NormalAbsentNormalN.A.90AbnormalAbsentNormalN.A. 65 y40AbnormalAbsentProlonged2.350AbnormalAbsentProlonged3.4 75 y70AbnormalAbsentProlonged2.250AbnormalAbsentProlonged1.0 83 y20NormalPresentProlonged2.320NormalPresentProlonged2.3 93 y80AbnormalAbsentProlonged2.380AbnormalAbsentProlonged2.9 101 y40AbnormalAbsentNormalN.A.40AbnormalAbsentNormalN.A. 11died*m* Months,*y* years,*EHT* estimated hearing threshold (dB HL, decibels hearing level),*Tymp* tympanogram result,*OAE* otoacoustic emission result,*I--V* auditory brainstem response inter-peak interval I to V,*III--V* auditory brainstem response inter-peak interval III to V (data are represented by z-scores, \>1.96 is considered abnormal), N.A. not applicable

Ten patients were followed for a maximum period of 6 years. One patient died at the age of 8 months. During the period that patients received enzyme therapy, the sensorineural hearing loss persisted in all with the exception of one patient, who had normal hearing at baseline. In addition, variable degrees of conductive hearing loss ranging from 15 to 60 dB were repeatedly found in nine patients (Fig. [1](#Fig1){ref-type="fig"}). Insertion of ventilation tubes in two patients did not improve their hearing levels. All patients (except patient 8) received hearing aids and/or speech therapy. Fig. 1Percentage of auditory brainstem responses (ABR) in which conductive hearing losses were found per patient. The number of ABRs performed per patients ranged from 1 (patient died at 5 months of age) to 18 and was on average 9

### Neurological involvement {#Sec10}

Waves I, III, and V were identified in all patients. Baseline nerve conduction patterns appeared to be close to normal for most of the patients. Inter-peak latency between peak I and peak V (IPL~I-V~) was prolonged in 3 patients (Table [2](#Tab2){ref-type="table"}, patients 6, 8, and 9).

During follow-up assessments, IPL~I-V~ remained prolonged in these three patients. Two other patients, who both had normal values at baseline, showed prolongation of IPL~I-V~ at the age of 1.5 years (patients 3 and 7). One of these patients started receiving enzyme therapy in the first month of life, the other at the age of 8 months when she was in an end stage of the disease. In both patients, IPL~I-V~ remained prolonged during the entire follow-up period. Further examination showed that a prolongation of the inter-peak latency was mainly found between peaks III and V.

Juvenile Pompe patients {#Sec11}
-----------------------

Age of the patients at their baseline hearing test ranged from 3 to 16.4 years (mean 11.4). Age at first symptoms ranged from 6 months to 10 years, and age at diagnosis ranged from 0.8 to 11.6 years. Patient characteristics are presented in Table [3](#Tab3){ref-type="table"}. Table 3Characteristics of 13 children with Pompe disease, and the amount of hearing lossPatientAge at hearing test (years)Gender (M/F)Motor status^a^Respiratory function^a^Hearing loss (dB)^a^(right ear)(left ear)113.1MAmbulant, prox weakNormalnhnh26.0MAmbulant, prox weakNormal33.3 condnh312.7FAmbulant, prox weakDiminishednhnh411.9MPartially wheelchair dep.Normalnhnh512.7FTetraplegicInvasive ventilation35 cond35 cond65.2MAmbulantNormalnhnh73MAmbulant, prox weakNormalnhnh816MAmbulantDiminishednhnh913MAmbulant, prox weakDiminishednhnh109FAmbulant, prox weakNormalnhnh1115.2MAmbulant, prox weakDiminished, BIPAPnhnh1216.4FParesis legs, scoliosisDiminished, BIPAPnhnh139.2FPartially wheelchair dep.Diminished, BIPAPnhnh*dB* Decibels,*nh* normal hearing*, cond* conductive hearing loss,*prox weak* proximal weakness,*BIPAP* bi-level positive airway pressure^a^Before start of enzyme replacement therapy

Pure-tone audiometry showed conductive hearing losses in patients 2 and 5. No hearing deficits were found in the other patients. Patient 2 had a mild unilateral conductive hearing loss of 33.3 dB. This patient exhibited mobility problems in early childhood, and was diagnosed with Pompe disease at the age of 3.5 years. At the age of 6 years, his auditory function was measured for the first time. At that moment, the patient was able to walk, and his pulmonary function was within normal limits. During follow-up examinations, the conductive hearing loss subsided, and test results became normal.

Patient 5 showed mild bilateral hearing loss during the first assessment in our hospital, at the age of 13 years. The patient was diagnosed with Pompe disease at the age of 2 years. In the following years, she followed a rapidly progressive disease course, became completely wheelchair bound, and was invasively ventilated at the age of 6. Severe weakness of the facial muscles caused dysarthria and dysphagia, for which she received feeding by percutaneous endoscopic gastroscopy tube. There was a medical history of persistent otitis media, for which she had received ventilation tubes at the age of 3 years. Additional examinations revealed a recurrent bilateral otitis media, and the hearing loss of 35 dB persisted during follow-up assessments.

Discussion {#Sec12}
==========

The present study confirms our previous finding that hearing disorders are a major concern in patients with the classic infantile form of Pompe disease (Kamphoven et al. [@CR7]). These problems are rarely found in children with milder forms of the disease. The reason why hearing loss selectively occurs in classic infantile patients is not fully understood, but may be explained by the less severe mutations and higher levels of residual α-glucosidase activity in juvenile patients.

The hearing deficits that we detected in 10 of 11 classic infantile patients ranged from 30 to 90 dB. As reported earlier, cochlear dysfunction was frequently found. But we also discovered additional conductive hearing losses in 75% of all hearing tests performed (in 90% of the patients). This is suggestive of chronic middle ear dysfunction. The etiology of chronic otitis media is multifactorial, and includes infectious, allergic, and immunologic factors resulting in Eustachian tube dysfunction and middle ear effusion (Mathew et al. [@CR14]; Tos [@CR21]). Our patients did not have clinical evidence for allergic or infectious middle ear problems, but we found severe weakness of the facial muscles in all classic infantile patients (Jones et al. [@CR5], and personal communication). The tensor veli palatini muscle is the principal muscle involved in opening the Eustachian tube. Weakness of this muscle has been reported to cause a pressure drop in the middle ear and may very well be the cause of the high incidence of conductive hearing loss found in infantile patients with Pompe disease.

To elucidate whether retrocochlear pathology was present in our classic infantile patient group, we studied repetitive ABRs. We found prolongation of inter-peak latencies in five patients. The most frequent finding was prolongation between peaks III and V. This is suggestive for pathology of the central part of the auditory pathway.

It was anticipated that glycogen storage in the brain and other parts of the central nervous system might cause sensorineural hearing loss (Kamphoven et al. [@CR7]), since glycogen storage has been found in nuclei of the brain stem, thalamus, anterior horn cells, and neurons of the spinal ganglia. Glycogen storage was also reported to be present in several parts of the brain of a patient that died during treatment with enzyme therapy. This finding was not unexpected since the intravenously administered enzyme cannot pass the blood--brain barrier (Thurberg et al. [@CR20]). Of note, three of the five patients with a prolongation of the inter-peak wave latencies belonged to the best responders to enzyme therapy. They were able to walk and had adequate cognitive abilities. Compared to other lysosomal storage disorders, like Gaucher type 3, the abnormalities in interpeak latencies were relatively mild. It is therefore suggested that glycogen storage, although undoubtedly present in brains of infants with Pompe disease, only minimally interferes with auditory functioning.

Hearing deficits were present shortly after birth. The extent of hearing loss did not decrease over time. This suggests that storage of glycogen in the cochlea already commences during gestation and that enzyme therapy does not have an effect on it. It should be noted, however, that there were variable degrees of conductive hearing loss, which interfered with the test results and prevented us from estimating the exact degree of sensorineural hearing loss.

In conclusion, our data emphasize that hearing problems are a major concern for patients with classic infantile Pompe disease, and are only sporadically present in children with milder forms of the disease. We therefore advise the monitoring of auditory function on a regular basis in infants with the disease, while regular examinations of auditory function are not required in older children. Retrocochlear pathology may be present, but does not seem to be a major contributor to the hearing problems. In addition to the previously reported cochlear hearing loss in infants, we found frequent conductive hearing losses in our patients. It is our experience that insertion of ventilation tubes does not consistently improve the hearing deficit. We therefore recommend early implementation of hearing devices, and speech therapy, in order to save precious time, especially since the first 2 years of life are most important for speech and language development (Zumach et al. [@CR28]).
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